He Yuxi, Zhang Yan, Su Guanfang
Department center of ophthalmology, The Second Hospital of Jilin University, China.
Curr Stem Cell Res Ther. 2015;10(3):258-65. doi: 10.2174/1574888x09666141027103552.
Retinitis pigmentosa (RP) is a group of inherited retinal disorders characterized by the progressive photoreceptors and pigment epithelial cells dysfunction. It is the most common retinal degeneration, responsible for loss of vision of most people worldwide. Until now its exact pathogenesis and etiology are not clear. So far there is no approved therapy. New approaches for RP therapy include cell transplantation, gene therapy, cytokine therapy, nutrition therapy, and hyperbaric oxygen therapy. Such therapies for retinal degenerative diseases are limited in their efficacy. This paper reviews the relevant documents, especially recent researches, and reviews advances in the treatment of RP.
视网膜色素变性(RP)是一组遗传性视网膜疾病,其特征为光感受器和色素上皮细胞进行性功能障碍。它是最常见的视网膜变性疾病,导致全球大多数人视力丧失。迄今为止,其确切的发病机制和病因尚不清楚。目前尚无获批的治疗方法。RP治疗的新方法包括细胞移植、基因治疗、细胞因子治疗、营养治疗和高压氧治疗。这些用于视网膜退行性疾病的治疗方法疗效有限。本文回顾了相关文献,尤其是近期的研究,并综述了RP治疗的进展。